Last reviewed · How we verify
Control - UFH
Unfractionated heparin (UFH) is an anticoagulant that inhibits multiple clotting factors to prevent blood clot formation.
Unfractionated heparin (UFH) is an anticoagulant that inhibits multiple clotting factors to prevent blood clot formation. Used for Acute venous thromboembolism (DVT/PE) treatment and prevention, Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.
At a glance
| Generic name | Control - UFH |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Anticoagulant (unfractionated heparin) |
| Target | Antithrombin III (enhancer); Factors IIa, Xa, and other serine proteases |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
UFH works by binding to and enhancing the activity of antithrombin III, a natural inhibitor of coagulation. This complex inactivates several key clotting factors (particularly factors IIa and Xa), preventing the formation and extension of fibrin clots. UFH is administered intravenously or subcutaneously and has a rapid onset of action, making it suitable for acute thrombotic conditions.
Approved indications
- Acute venous thromboembolism (DVT/PE) treatment and prevention
- Acute coronary syndrome
- Atrial fibrillation with thromboembolism risk
- Cardiopulmonary bypass anticoagulation
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis
- Osteoporosis (with prolonged use)
- Hyperkalemia
- Injection site reactions
Key clinical trials
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia (PHASE2)
- Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial (NA)
- Comparison of Two Pulmonary Embolism Treatments (NA)
- Nebulised Heparin in Patients With Severe COVID-19 (PHASE2, PHASE3)
- Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy (PHASE2)
- Mechanical Thrombectomy for Acute Pulmonary Embolism (EARLY_PHASE1)
- Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control - UFH CI brief — competitive landscape report
- Control - UFH updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI